Sitravatinib Targets TYRO3 to Augment the Anti-Tumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma

Human HCC cell lines and xenograft models were used to explore the anti-tumor activity of sitravatinib. Subcutaneous and orthotopic immunocompetent murine HCC models were used to assess the therapeutic efficacy of sitravatinib and PD-1 blockade combination therapy.